Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. develops live biotherapeutic products and microbiome-based therapies for inflammatory, immune, infectious and gastrointestinal diseases. Company updates commonly address pipeline programs such as SER-155 for immune checkpoint inhibitor-related enterocolitis and prevention of bloodstream infections in allogeneic hematopoietic stem cell transplant patients, SER-603 for inflammatory bowel disease, and SER-428 for antimicrobial resistance and serious infections.
Recurring announcements include financial results, operational updates, research publications, scientific conference presentations, biomarker and microbiome-mechanism data, collaborations, financing and partnership activity, cost-control measures, and governance changes.
Seres Therapeutics (Nasdaq: MCRB) has announced positive Phase 3 results from the ECOSPOR III trial of SER-109, presented at the Virtual ACG Annual Meeting. The trial demonstrated a statistically significant reduction in C. difficile infection recurrence at 12 weeks post-treatment, with a 31.1% absolute risk reduction compared to placebo. The study included 182 patients and confirmed the therapy's efficacy across age groups. SER-109 aims to transform treatment for recurrent C. difficile infection, having received FDA Breakthrough Therapy and Orphan Drug designations.